BR0113073A - Uso de antagonistas receptores 5ht4 na fabricação de um medicamento para a profilaxia ou tratamento de fibrilação atrial - Google Patents

Uso de antagonistas receptores 5ht4 na fabricação de um medicamento para a profilaxia ou tratamento de fibrilação atrial

Info

Publication number
BR0113073A
BR0113073A BR0113073-0A BR0113073A BR0113073A BR 0113073 A BR0113073 A BR 0113073A BR 0113073 A BR0113073 A BR 0113073A BR 0113073 A BR0113073 A BR 0113073A
Authority
BR
Brazil
Prior art keywords
treatment
prophylaxis
manufacture
mammal
medicament
Prior art date
Application number
BR0113073-0A
Other languages
English (en)
Inventor
Mireille Marguerite J Bonhomme
Antoine Michel Alain Bril
Bernard Emile Joseph Gout
Bela Rajiv Patel
Gillian Louise Shepherd
Original Assignee
Glaxosmithkline Lab Sas
Smithkline Beecham Corp
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019410A external-priority patent/GB0019410D0/en
Priority claimed from GB0019523A external-priority patent/GB0019523D0/en
Priority claimed from GB0019524A external-priority patent/GB0019524D0/en
Priority claimed from GB0118919A external-priority patent/GB0118919D0/en
Priority claimed from GB0119022A external-priority patent/GB0119022D0/en
Application filed by Glaxosmithkline Lab Sas, Smithkline Beecham Corp, Glaxo Group Ltd filed Critical Glaxosmithkline Lab Sas
Publication of BR0113073A publication Critical patent/BR0113073A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE ANTAGONISTAS RECEPTORES 5HT4 NA FABRICAçãO DE UM MEDICAMENTO PARA A PROFILAXIA OU TRATAMENTO DE FIBRILAçãO ATRIAL". A invenção refere-se ao uso de um antagonista receptor 5-HT, na fabricação de um medicamento para a profilaxia ou tratamento de remodelagem atrial em um mamífero. Preferivelmente, o antagonista é N- [ (1-^ n^ butil-4-piperidinil)metil]-3,4-diidro-2H-[1,3]oxazino[3,2-a]indol-10-carb oxamida (SB 207266) ou um seu sal farmaceuticamente aceitável. A invenção também se refere ao uso de SB 207266 ou um seu sal farmaceuticamente aceitável na fabricação de um medicamento para o tratamento ou profilaxia de fibrilação atrial em um mamífero por administração ao mamífero de um regime de dosagem oral ou parenteral diária de aproximadamente 0,2 mg a 1,0 mg do SB 207266 ou um seu sal por kg de peso corpóreo total (medido como a base livre). A invenção também se refere ao uso de SB 207266 ou um seu sal farmaceuticamente aceitável na profilaxia ou tratamento de arritmia atrial em um mamífero pela administração do SB 207266 ou um seu sal no primeiro dia em uma dose de carga de aproximadamente 1,2 a aproximadamente 2,0 vezes a dose de manutenção diária, seguido por administração do SB 207266 ou sal na dose de manutenção diária em dias subsequentes.
BR0113073-0A 2000-08-07 2001-08-07 Uso de antagonistas receptores 5ht4 na fabricação de um medicamento para a profilaxia ou tratamento de fibrilação atrial BR0113073A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0019410A GB0019410D0 (en) 2000-08-07 2000-08-07 Novel use
GB0019523A GB0019523D0 (en) 2000-08-08 2000-08-08 Novel use
GB0019524A GB0019524D0 (en) 2000-08-08 2000-08-08 Novel use
GB0118919A GB0118919D0 (en) 2001-08-02 2001-08-02 Novel use
GB0119022A GB0119022D0 (en) 2001-08-03 2001-08-03 Novel use
PCT/GB2001/003544 WO2002011766A2 (en) 2000-08-07 2001-08-07 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation

Publications (1)

Publication Number Publication Date
BR0113073A true BR0113073A (pt) 2004-06-22

Family

ID=27515972

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113073-0A BR0113073A (pt) 2000-08-07 2001-08-07 Uso de antagonistas receptores 5ht4 na fabricação de um medicamento para a profilaxia ou tratamento de fibrilação atrial

Country Status (16)

Country Link
US (3) US20050032866A1 (pt)
EP (1) EP1311295A2 (pt)
JP (2) JP2004505930A (pt)
KR (1) KR20030027010A (pt)
CN (1) CN100413539C (pt)
AU (1) AU781276B2 (pt)
BR (1) BR0113073A (pt)
CA (1) CA2418904A1 (pt)
CZ (1) CZ2003366A3 (pt)
HU (1) HUP0303075A3 (pt)
IL (1) IL154279A0 (pt)
MX (1) MXPA03001210A (pt)
NO (1) NO20030588L (pt)
NZ (1) NZ524108A (pt)
PL (1) PL365048A1 (pt)
WO (1) WO2002011766A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1476136E (pt) * 2002-02-14 2006-10-31 Glaxo Group Ltd Composicao farmaceutica compreendendo n-((1-n-butil-4-piperidinil)metil)-3,4-di-hidro-2h-(1,3) oxazino (3,2-a) indole-10-carboxamida ou sal e processo de a obter compreendendo granulacao a seco.
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EP2366431A1 (en) * 2010-03-19 2011-09-21 Universitätsklinikum Hamburg-Eppendorf Myeloperoxidase as a target in atrial fibrillation
JP6574773B2 (ja) 2014-07-30 2019-09-11 株式会社アエタスファルマ １，４−ベンゾチアゼピン−１−オキシド誘導体の光学異性体、及びそれを用いた医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009389D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Treatment
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
SG49153A1 (en) * 1991-09-12 1998-05-18 Smithkline Beecham Plc 5-HT4 receptor antagonists
MA22647A1 (fr) * 1991-09-14 1993-04-01 Smithkline Beecham Plc Procede de preparation d'un ester ou d'un amide d'un nouveau produit .
WO1993018036A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Condensed indole derivatives as 5ht4-receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
MX9301837A (es) * 1992-03-31 1994-02-28 Glaxo Group Ltd Ureas y fenilcarbamatos substituidos, proceso para su preparacion y composicion farmaceutica que los comprende.
GB9206989D0 (en) * 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
CA2133083A1 (en) * 1992-03-31 1993-10-14 Alexander W. Oxford Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht antagonists
AU680004B2 (en) * 1993-05-26 1997-07-17 Syntex (U.S.A.) Inc. Novel 1-phenylalkanone 5-HT4 receptor ligands
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JP3911297B2 (ja) * 1996-08-16 2007-05-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｎ―［（１―ｎブチル―４―ピペリジル）メチル］―３，４―ジヒドロ―２Ｈ―［１，３］オキサジノ［３，２―ａ］インドール―１０―カルボキシアミドおよび塩ならびに製造における中間体
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide

Also Published As

Publication number Publication date
CA2418904A1 (en) 2002-02-14
AU781276B2 (en) 2005-05-12
NO20030588D0 (no) 2003-02-06
KR20030027010A (ko) 2003-04-03
US20070015769A1 (en) 2007-01-18
CN1468112A (zh) 2004-01-14
US20080125422A1 (en) 2008-05-29
IL154279A0 (en) 2003-09-17
HUP0303075A2 (hu) 2003-12-29
HUP0303075A3 (en) 2007-03-28
AU7652901A (en) 2002-02-18
US20050032866A1 (en) 2005-02-10
MXPA03001210A (es) 2004-08-12
JP2004505930A (ja) 2004-02-26
CZ2003366A3 (en) 2004-04-14
NZ524108A (en) 2004-11-26
WO2002011766A2 (en) 2002-02-14
PL365048A1 (en) 2004-12-27
EP1311295A2 (en) 2003-05-21
JP2007145869A (ja) 2007-06-14
WO2002011766A3 (en) 2002-08-01
NO20030588L (no) 2003-04-03
CN100413539C (zh) 2008-08-27

Similar Documents

Publication Publication Date Title
JP4925074B2 (ja) ミルタザピンと１種以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物
US8969400B2 (en) Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
US20170157134A1 (en) Combination therapy
JPH0324447B2 (pt)
JPS6233204B2 (pt)
US20190192525A1 (en) Apilimod compositions and methods for using same
KR19990067698A (ko) 세로토닌 재흡수 억제제의 위장 효과를 극복하기 위한 5ht4수용체 길항제의 용도
KR20010032009A (ko) 수면성 무호흡의 치료에 미타자핀을 사용하는 방법
AU2014279721A1 (en) Pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent
BR0113073A (pt) Uso de antagonistas receptores 5ht4 na fabricação de um medicamento para a profilaxia ou tratamento de fibrilação atrial
CA2522971A1 (en) Method of improved diuresis in individuals with impaired renal function
AU2006226390B2 (en) Benzamidine derivatives for treatment and prevention of cancer therapy induced mucositis
NO319421B1 (no) Terapeutisk bruk av melatonin
NZ535261A (en) A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
CA2100777C (en) Pharmaceutical composition containing granisetron and dexamethasone
MXPA01010340A (es) Osanetant en el tratamiento de transtornos del humor.
ES2303585T3 (es) Combinacion de glivec(sti571) con un inhibidor de quinasa dependiente de ciclina, especialmente flavopiridol en el tratamiento de cancer.
AR030145A1 (es) Sal farmaceuticamente aceptable de morfolinobenzamida o solvato de la misma, formulacion farmaceutica que la contiene, su uso para la fabricacion de un medicamento y proceso para la preparacion de dicha sal o solvato
CA2816601A1 (en) Dexamethasone combination therapy
CA2417677A1 (en) Medicaments containing cilansetron for treating non-obstipated male ibs patients
US3833727A (en) Hydralazine and beta-adrenergic blocking agent compositions for treating hypertension
ES2963706T3 (es) Masitinib para el tratamiento del cáncer de próstata resistente a la castración
JPH03502802A (ja) 抗嘔吐性エルゴリン誘導体
US7842702B2 (en) Treatment for irritable bowel syndrome
CA2538523A1 (en) Treatment of gastrointestinal stromal tumors with imatinib and midostaurin

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012.